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The variety of factors controlling the onset of
parturition, äs well äs the very complex mecha-
nisms which physiologically maintain pregnancy
by inhibiting uterine contractions are only
partially understood today. As long äs the
triggering mechanisms, and the conditions favor-
ing timely and early labor are incompletely
known, symptomatic therapeutic attempts aim
at blocking unwanted contractile activity of
the uterine smooth muscle fibres. The high
rates of neonatal mortality and morbidity asso-
ciated with premature births [52] have stimulated
efforts to find agents which safely inhibit uterine
contractions in humans.
1. Inhibition of uterine activity by /?-mimetic
agents
A theoretic basis has been provided by AHL-
QUIST'S [2] concept of adrenergic <x- and ß-
receptors, which can also be appÜed to the
pregnant uterus [3, 18, 19]: Stimulation of the
myometrial /?-adrenergic receptors causes re-
laxation of the uterine muscle in pregnancy.
Since the 1960's a series of ß-mimetic uterus-
inhibiting catecholamine derivatives have been
synthesized and tested. Their chemical constitu-
tions, the basic theoretic considerations for their
clinical use, and the increasingly successful use
in the treatment and the management of pre-
mature and excessive labor have been reviewed
recently[19,20,29,3Ö,32,42,75]. The most fre-
quently used compounds are: Isoxsuprine =
Duvadilan, Vasodilan; Ritodrine = Du 21220;
Buphenin = Nylidrin, Dilatol; TV 399; Th
1165a.
The dose-dependent Inhibition of uterine con-
tractions and suppression of intra-amniotic pres-
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In Tab. I some clinical results in the treatment of
premature labor are summarized.
In spite of the wide application of adrenergic
jß-mimetic agents to inhibit premature labor, the
fetakieonatal effects of the compounds used have
been rather poorly evaluated in the past.
2. The complex of the ß-stimulated res-
ponse
An approach to the evaluation of the possible
influences of tocolytic catecholamine derivatives
on the fetus has to Start from the fact that the
relaxation of uterine smooth muscle is only one
component of the ß-stimulated response. The
spectrum of effects triggered off by the /?-adren-
ergic Stimulus additionally consists of cardio
vascular and metabolic reactions [24].
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Tab. I. Clinical results of ß-mimetic therapy for the prevention o£ premature births.
Criteria: A = Temporary arrest of labor
B = Prevention of premature birth
C = Prolongation of pregnancy, average of time
D = Newborns over 2500 g
F = Failure





















































7—21 days 6 of 19
2—6 days 12 of 19










1. Positive chronotropic and positive inotropic
Stimulation of the myocardium cause tachy-
cardia.
2. Vasodilatation increases the peripheral blood-
flow.
3. Systolic and diastolic hypotonia.
B) Metabolie reactions: Stimulation of the
cell membrane enzyme adenyl cyclase, which
cätalyzes the intracellular formation of cyclic
3'5'-adenosine monophosphate from adenosine




Glycogenolysis and lipolysis are estbalished ß-
mimetic effects, and result in marked changes in
intra- and extracellular concentrations of car-
bohydrate- and fat metabolites.
The evaluation of possible fetal-neonatal in-
fluences of tocolytic catecholamine derivatives
has to take into consideration the whole pattern
of ß-stimulated responses.
3. Influence upon the fetus, and possibilities
of evaluating these effects
The fetal organism may be involved in two ways,
which may act in conjunction:
A) 1. Maternal cardiovascular reactions to
/?-mimetic drugs influence the utero-placental and
fetal circulation.
2. According to the level of maternal concen-
trations, carbohydrate- and fat metabolites
are increasingly transferred accross the pla-
centa causing alterations of the fetal metabolic
homeostasis.
B) The tocolytic substances are readily trans-
ferred across the placenta and induce the
complete typical pattern of ß-stimulated responses
in the fetal organism itself.
In contrast to the mother, the fetus is generally
not accessible for assays of metabolism. Successful
administration of *-tocolytics with Inhibition of
premature labor and advancement of parturition
almost exclude availability of the fetus and new-
born to direct investigations of biochemical
Parameters. Studies of the fetal Situation during
tocolytic therapy are therefore mainly restricted
J. Perinat. Mcd. 2 (1974)
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to the observation of fetal-heart-rate-patterns. The
methods used are fetal phono- or electrocardio-
graphy and the ultrasonic Doppler-signal. Other
useful parameters are in some cases amnioscopy,
and during long-time application continous
measurement of oestriol- and human placental
lactogen concentrations, together with ultrasound
cephalometry. Some investigators have admin
istered tocolytics during an advanced stage of
parturition and collected micro-blood-specimens
from the presenting part for blood-gas-analysis.
In other cases newborns were examined following
failure of tocolytic therapy.
4. Cardiovascular effects
In the concentrations essential for tocolytic
efficiency all the adrenergic ß-mimetic com-
pounds affect the cardiovascular System,
occasionally to a significant degree, thus limiting
their clinical usefulness. The maternal hypo-
tensive and cardioaccelatory efFects associated
with the use of /?-mimetic tocolytics have been
emphasized by many authors [4, 5, 6, 7, 8, 11, 12,
16, 28, 29, 31, 36, 39, 43, 45, 46, 49, 54, 57, 58, 63,
66, 67, 68, 69, 72],
Additional administration of Iproveratril has
proved to be efficient in reducing the maternal
cardiovascular side effects. Moreover this com-
pound may act synergistically with the /?-mimetics
in inhibiting uterine activity [42, 43, 49, 52, 64],
4.1 Influence upon fetal circulation
The influence of ß-mimetic catecholamines upon
the fetal circulation has been reviewed by ESKES
and DE HAAN recently [21]. Usually the fetal
heart rate increases during infusion of ß-
mimetics [10, 21, 29, 31, 45, 57, 62, 67]. During
infusion of 0.05—0.2mg Ritodrine/min, how-
ever, some authors found no significant accele^
ration of the fetal heart rate [5, 8, 66], even
when maternal tachycardia was significant [36],
Also with Ritodrine concentrations äs high äs
0.38 mg/min the fetal heart rate remained within
the limits of normal values, while a moderate
acceleration in maternal heart rate from 70 to
105 beats/min was significant [11]. With Orci-
prenaline (0.02—0.04 mg/min i. v.) a moderate
increase of the fetal heart rate appeared 30 min
after start of infusion [72]. When 0.1—0.6mg/
min Du 21220 were given intravenously during
parturition, the increase of maternal heart rate
was dose-dependent. The fetal heart rate
acceleration, however, did not display this
relationship [25]. With 1.5—3.0^g/min Th
1165 a i. v. a fetal tachycardia of +3% was
observed, which in contrast to the mother
started later and reached a maximum of +5%
when the infusion had already ended [29].
According to these results, fetal heart rate
acceleration during administration of ß-
mimetic tocolytics is independent of maternal
tachycardia. The fetal tachycardia presumably
indicates that tocolytic agents, having crossed
the placenta, directly stimulate the ß-receptors in
the fetal myocardium [31, 57, 72].
ESKES and DE HAAN [21] studied six aspects of
fetal heart rate by a method of Computer eva-
luation. The /?-mimetic catecholamines did not
influence the patterns of short-time irregularity,
except when the basal heart frequency increased
to over 150 beats/min.
No changes of the fetal electrocardiogram
were observed by several authors using Isox-
suprine [6, 56, 57].
4.2 Infusion of /?-mimetric in lateral position
Maternal cardiovascular reaction to tocolytic
jS-mimetic drugs, however, can have a profound
influence on the fetal circulation, when severe
maternal hypotension occurs [21]. During
infusion of /?-mimetics in the supine position, a
breakdown of the uteroplacental bloodflow
with its detrimental effects on the fetus results
from a supine hypotensive syndrome [19, 29, 57].
CRAWFORD [15] noted that frequently a decreased
venous return is compensated for a time by
vasoconstriction. In those cases ß-stimulated
peripheral vasodilatation may antagonize this
endogenous compensation, endangering the utero-
placental blood-flow. Therefore a lateral po-
sition during infusion of /5-mimetic tocolytics
is generally recommended.
4.3 Failure of the placental respiratory func-
tion
On the other hand, /?-stimulated peripheral
vasodilatation together with a wider pulse
J. Pcrinat. Med. 2 (1974) 2*
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amplitude, resulting from unchanged systolic
blood pressure when the diastolic tension is
lowered [69], and an increased maternal cardiac
Output consequently enhance placental perfusion,
improving the oxygen supply to the fetus. This
is especially the case when this effect is additional
to the desired relaxation of the Uterus. When
chronic placental insufficiency exists, normal
labor contractions and especially hyperactive
contractions are likely to produce an acute
failure of the placental respiratory function.
Diminution of frequency and intensity of uterine
contractions, äs well äs reduction of the uterine
basal tonus by tocolytics interfere with the
pathophysiological mechanisms of acute placental
insufficiency [50]. GAMISSANS, ESTEBAN-ALTIR-
RIBA and MAIQUES [25] observed in their series
of sub partu Ritodrine-treated patients two cases
^with a fetal capillary pH of 7.18 and 7.22 res-
pectively. The cardiotocogram displayed late
decelerations. When uterine activity decreased
during administration of Ritodrine, the late
decelerations disappeared and the fetal pH rose
to 7.24 and 7.27 respectively. In 4 other patient's
fetal pH-values increased within normal ranges
after Inhibition of uterine activity. In further
investigations these authors studied the use-
fulness of intravenous Infusion of tocolytics
for the treatment of intra partum fetal acidosis.
In most of their patients they were able to
achieve a significant rise of former acidotic or
preacidotic fetal capillary pH values together
with the Inhibition of labor contractions. Fetal
Pco2 decreased in cases of respiratory and mixed
acidosis, and tended to increase when metabolic
acidosis prevailed [26]. According to their
results with a group of another 41 cases of
suspected intra partum fetal acidosis due to
uterine hyperactivity or cord compression, they
now recommend a 15 minute-treatment trial
with tocolytic infusion, before the fetus is
delivered [22].
KÜNZEL and REINECKE during 20 min infusion
of 0.03 Th 1165 a/min/kg body weight intra
partum found an increase of fetal capillary blood
Po2 from 15.6 to 18.2 mm Hg. Fetal oxygen
Saturation was elevated from 31.5 to 38.4%, pH
and Pco2 remained unchanged., These results,
corresponding to an increase of fetal capillary
blood oxygen concentration of 1.5 ml/100 ml
were supposed to be due to better uterine per-
fusion during /?-mimetic relaxation of the uterus
[35].
4.4 /?-mimetics in EPH-gestosis
VAHRSON and SCHWARZ [63] reported 12 cases of
severe EPH-gestosis where a reduction of
systolic and diastolic hypertension was brought
about by intravenous infusion of Buphenin
without impairing the oxygen supply to the
fetus.
Normalization of hypertension, increased
uteroplacental blood-flow by peripheral vaso-
dilatation with improved intrauterine con-
ditions for the dysmature and placental-
insufficiency-endangered fetus are the basis for
therapeutic long-time trials in EPH-gestosis [42].
This mode of action may also explain some
authors' observations of increased biparietal
diameters and higher birth-weights following
long-time administration of ß-mimetics [29, 49,
52].
5. Effects upon carbohydrate and fat
metabolism
Another Interpretation of possibly increased
fetal growth during tocolytic long-time therapy
may be given by continuously elevated maternal
blood glucose levels, resulting from jö-mimetic
effects upon carbohydrate metabolism. Contrast
to the well known and thoroughly studied mater-
nal cardiovascular alterations caused by ß-
mimetic tocolytics, the metabolic effects of the
compounds used have not been sufficiently
noticed until recently. JUNG, ABRAMOWSKI,
KLÖCK and SCHWENZEL [31] reported an im-
mediate severe increase of blood glucose
concentrations, together with glycosuria and
ketonuria in a pregnant diabetic during
tocolytic jtreatment. LIPPERT, KUBLI and RÜTT-
GERS [38] demonstrated the hyperglycemic
activity of Isoxsuprine and Buphenin in pregnant
women. 60 minutes after the intramuscular in-
jection of 5 mg Buphenin the blood glucose
concentration had risen to 150% of the starting
level. 10 mg Isoxsuprine, however, caused only a
non-significant increase of 8.6%. They also found
marked hyperglycemia, glycosuria and aceton-
J. Perinat. Med. 2 (1974)
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uria following administration of Isoxsuprine or
Buphenin to diabetic pregnant women.
More detailed examinations of ß-mimetic efFects
upon carbohydrate and fat metabolism during
tocolytic therapy have been reported lately by
some groups of investigators. During oral, intra-
muscular or intravenous application of Dilatol
or Th 1165 a maternal blood glucose levels
increased 10—40% above the starting level;
when Dilatol is infused intravenously, maternal
glucose concentration doubled immediately [55],
50—260 (average 90 ^ g) Dylidrin/min i. v.
caused an increase of maternal glucose from 82
to 140 mg/100 ml [51]. At the time, 1/jg Th
1165 a/min is infused for 24—48 hrs, and daily
variations in blood glucose concentrations are
likewise elevated [37].
After 5mg Th 1165 had been given orally,
pregnant women without uterine contractions
reacted with an average increase of 40 mg/100 ml
in blood glucose within 90 min. Another 90 min
later, glucose levels had normalized [64], Patho-
logie high blood glucose concentrations were
found following an oral glucose load of 50 g
during Dilatol- or Th 1165 a therapy [55].
Glucose assimilation has been found unchanged
by some [64], others, however, have reported an
impairment of glucose assimilation following a
combined insulin-glucose-tolerance test during
tocolytic therapy [37], After oral administration
of 5 mg Th 1165 a maternal insulin concen-
trations were found increased, following the
rise of glucose concentrations with a short
time-lag [64]. During long-time application
other authors determined rather low levels of
maternal insulin concentrations [37]. When
3^g Th 1165 a/min were infused intravenously
for 4 hours in a homogeneous group of normal
healthy pregnant women at term, not in labor
and having fasted for 8 hours, blood glucose
concentrations showed a continous rise which
became significant after 60 min. A the same time
the insulin concentrations were 5 times higher
than the starting levels and decreased slightly in
the following 3 hours. Free fatty acids and free
glycerol concentrations doubled, lactate and
pyruvate concentrations rose continously, reach-
ing levels 3 times higher than at the Start of the
infusion. Acetoacetate and /J-hydroxybutyrate
concentrations rose immediately when the
ß-mimetic was infused. Having reached a 2—2.5
fold increase, beginning from the second
hour, acetoacetate and ß-hydroxybutyrate de-
clined slowly, free fatty acids and free glycerol
acted in the same way, while the concentrations
of neutral fats, total glycerol and esterified gly-
cerol were changed at first, showing an increase
from the second hour until the end of the in-
fusion. Within 60 min after the end of the
infusion, nearly all the changes of metabolite
concentrations had normalized with the excep-
tion of the pyruvate and lactate levels [14,61,62].
15min after starting an infusion of 0.12mg
TV 399/min in pregnancies at term without
uterine contractions, maternal lactate concen-
trations increased from 11.51 to 24.94 mg/100 ml,
the pyruvate concentrations rose from 0.256 to
0.392 mg/100 ml. Maternal actual pH values
appeared to be rather on the acid side [45], Also
WOLFF [70] reported a decrease in maternal
base excess and actual pH, still within normal
ranges, 15 min after the end of a 60 min in-
fusion of 0.17 mg Dilatol/min.
During infusion of 2/jg Th 1165 a/min at the
beginning of the first stage of labor, maternal
actual pH, äs well äs base excess decreased sig-
nificantly, Po2 and Pco2 underwent no signi-
ficant changes [33]. When 0.1 mg Buphenin/min
is used under similar conditions, maternal acid-
base parameters remain unchanged [33, 51].
5.1 Potassium concentration during infusion
of /?-mimetics
Another response typical for ß-mimetic com-
pounds is a decrease in plasma potassium con-
centrations, resulting from a shift in the intra-
cellular — extracellular potassium balance [23,
40]. During infusion of 3^g Th 1165 a/min a
highly significant rapid fall of potassium con-
centrations in maternal serum was found, reach-
ing levels äs low äs 2.8 mval/1. 60 min after the
end of the infusion the potassium concentrations
had recovered [61, 62].
J. Pcrinat. Med. 2 (1974)
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5.2 Changes in maternal metabolism hydroxybutyrate readily pass across the placenta
into the fetal organism. Maternal high concen-
Summarizing these corresponding results, it can
 tration§ of acid metabolites are most likely to
be concluded that immediately after startmg a
 duce ft feftd metabolic acidosis. In contrast
tocolytic therapy by an infusion of 0-mimettc ^ ^ ^
 low.mokcular acids> free fatty
agents lipolysis and glycogenolysis are tng- ^.^ ^
 bouiid tQ albumin and cannot
gered off. The glycogen reserves are mobilized. ^^ ^
 piacenta [74],
High lactate levels are mainly evidence of hydro-
lysis of muscle glycogen. Acute lipolytic mobi- ge Placental transfer and metabolism of
lizing of fat reserves causes increases of free fatty catecholamines
acids, the high concentrations of which evidently
 Catecholamines do cross the placental mem-
block the metabolizing of acetyl-co-A, thus
 branes ^ humanSe When i4C_iabelled norepine-
leading to excessive high levels of ketone bodies.
 phrine was injected into the mother before birth
After this has continued f or some time, however,
 Q£ non.viable £etuseSj appreciable amounts of
compensating mechanisms come into force.
 radioactivity were recovered from umbilical
Increased insulin levels followmg elevated
 cord. and fetal heart blood [53]. ZUSPAN, WHALEY,
glucose concentrations support glucose assi-
 NELSON and AHLQUIST [74] concluded from the
milation. In addition, increased lactate con-
 Wgh increase of glucose concentrations in fetal
pentrations may flow into gluconeogenesis.
 blood following epinephrine infusion to the
Resynthesis of neutral fats is enhanced, ketone
 mother^ that sufficient epinephrine had passed
body concentrations decrease, and the acute
 acrQSS the placenta to -mducc additional glucose
alterations balance. mobilization in the fetus. MORGAN, SANDLER
The changes in maternal acid-base parameters, and PANIGEL [41] were able to demonstrate a
which indicate an acute metabolic acidosis rapid transfer of the catecholamines norepine-
during infusion of ß-mimetic tocolytics concur phrine and isoproterenol from the maternal to the
well with these findings. After Inhibition of fetal side in perfused human placentas in vitro,
uterine contractions in the first stage of labor by
infusion of O.lmg TV 399/min or 2.5 § Th 6.1 Placental enzymes
1165 a/min actual pH values from fetal scalp During the placental passage, however, the
capillary blood were found to be within normal catecholamines to some extent undergo metaboli-
ranges [31]. When maternal base excess and pH zation and inactivation. Placental tissues contain
decreased during infusion of Dilatol, these rather high activities of the two main catechol-
parameters changed in the way in the capillary amine degrading enzymes: monoamine oxidase
blood [70]. During infusion of 2 § Th 1165 a/ and catechol-O-methyl transferase [13, 41, 60].
min, in accordance with maternal changes, fetal The placental monoamine oxidase, like the en-
actual pH and base excess were significantly zymes in the liver, kidney and elsewhere can
lowered, whereas Po2 and Pco2 remained un- oxidize a number of aromatic monoamines, but
altered [33]. Maternal hyperglycemia during in- is inactive against diamines like histamine. Again
fusion of Dilydrin is rapidly reflected in the fetus like the liver enzyme, the activity of the placental
[51]. Fetal pH values are within the normal ränge enzyme is proportional to the oxygen tension of
in the umbilical artery; however, there is a the medium in which it acts [60]. Macroscopic
tendency for them to decrease; Pco2, Po2 and regressive altered placental tissue metabolizes
O2-saturation display no alterations [51]. Rises of less 3H-norepinephrine than normal tissue [13].
maternal lactate and pyruvate concentrations Catechol-O-methyl transferase of placental tissue
during infusion of TV 399 were consistent with was also shown to be able to catalyze O-methyl-
an increase of fetal lactate and pyruvate concen- ation of isoproterenol, a typical ß-mimetic
trations, while pH and base excess decreased [45]. catecholamine derivative [41].
There can be no doubt that small molecules like From these results it can be presumed that these
glucose, lactate, pyruvate, acetoacetate and ß- placental enzymes play a role in defending the
J. Pcrinat. Med. 2 (1974)
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fetus from the damaging access of catecholamines
into its circulation [41].
Also uterine tissue contains both the enzyme
activities [13, 60], Moreover, the fetus and new-
born themselves appear to be equipped with the
two key catecholamine degrading enzymes in
their own right [17, 48]. Catechol-O-methyl
transferase is found in human liver before birth,
and its activity increases with age [1]. In livers of
fetuses at the 3rd—4th month of gestation, high
activities of monoamine oxidase and catechol-O-
methyl transferase are present. Brain and heart
tissues contain catechol-O-methyl transferase but
less monoamine oxidase activities [13], The
authors [l, 13] suggest that in an early state in
fetal tissues catecholamines are mainly degraded
by catechol-O-methyl transferase, monoamine
oxidase gaining importance later.
In a case of phaeochromocytoma in pregnancy,
distinctly lower catecholamine concentrations
were observed in umbilical blood than in maternal
blood, presumably due to vigorous inactivation
[59]. Increased induction of the catecholamine
metabolizing enzymes by the continous high
Substrate supply may be discussed in such cases.
6.2 Changes in fetal metabolism
According to the results described above, it has
to be taken into consideration that during ß-
mimetic tocolytic therapy glycogenolysis and
lipolysis occur in the mother äs well äs in
the fetus. If after 2—3 hours of jS-mimetic
tocolytic infusion the therapy fails, a metabolic
acidosis, resulting from increased concentrations
of acid metabolites: lactate, acetoacetate, ß-
hydroxybutyrate in the fetus has to be anticipated.
The glycogen reserves may be depleted, and fetal
hypoglycemia is subsequently endangering the
newborn. After a longer-lasting therapy, however,
the initial ß-stimulated metabolic changes have
balanced out and are likely tobe of less importance.
A first report on 51 children, born after long-
time tocolysis with Th 1165 a, who were
thoroughly followed up biochemically and
neurologically to the age of 18 months did not
reveal any impairments [65].
Recent results indicate that Estriol- and HPL-
concentrations may have a tendency to
increase of less than the normal rate during
long-time /?-mimetic therapy, though growth
of the fetal biparietal diameter is regulär at
the same time [27].
4 cases of sudden intrauterine death during
tocolytic therapy have been reported [4, 47, 62].
In 3 of these stillbirths regressive changes and
fibrocalcific deposits were found in the placenta.
Recently ZLATNIK [73} emphasized that labor
Inhibition is applicable only to a minority of
patients with impending premature births,
thus reducing over-optimistic expectations. In
addition to regarding the well-outlined contra-
indications of tocolytic therapy, an assessment
of the fetal condition has to be conducted.When
faulty intrauterine environments exist be-
cause of poor maternal nutrition, reduced
uterine bloöd-flow, chronic maternal disease,
a pte-term delivery under careful monitoring
would be more suitable than an useless pro-
longation of the pregnancy.
Summary
jS-Mimetic catecholamines have been proved useful in
the treatment of threatening premature births (Tab. I).
The fetalneonatal effects of the substances used have been
evaluated rather poorly until recently. Adrenergic ß-
stimulation releases a complex of different responses, of
which the relaxation of uterine muscle is only one com-
ponent. Other important ß-stimulated effects ate car-
dioaccelatory, vasodilatory and hypotensive äs well äs
glycogenolytic and lipolytic reactions. The evaluation
of influences on the fetus, associated with /?-mimetic
tocolysis has to take into consideration the whole pattern
of /?-stimulated cardiovascular and metabolic responses.
The fetus is involved in two ways: 1. The maternal cardio-
vascular and metabolic alterations affect the fetus indirectly,
2. The tocolytic agent is transferred across the placenta and
is triggering the same responses in the fetal organism
itself. Maternal hypotension, induced by tocolysis can
have detrimental consequences for the fetus, especially
when a supine hypotensive syndrome is favoured and the
utero-placental blood-flow collapses. A lateral position
during infusion of /3-mimetic tocolytics is recommend-
ed. On the other hand, j9-stimulated peripheral vaso-
dilatation, together with a wider pulse amplitude, which
results from unchanged systolic blood pressure when the
J. Pcrinat. Med. 2 (1974)
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diastolic tension is lowered, and an increased maternal
cardiac Output, consequently enhance placental per-
fusion, improving the oxygen supply to the fetus. In
particular this is the case, when this effect is additional to
the desired relaxation of the Uterus, or when a chronic
placental insufficiency exists.
Higher birth-weight after long-time administration of
tocolytic jf?-mimetics may be explained by better utero-
placental circulation, and or by increased blood glucose
levels. Immediately after starting a tocolytic infusion of
/8-mimetics, lipolysis and glycogenolysis are triggered.
The glycogen depots are mobilized. High lactate levels
indicate preferred hydrolysis of muscle glycogen.
Acute lipolytic mobilizing of neutral fat depots causes
increase of free fatty acids, the high concentrations of
which evidently block the metabolizing of acetyl-co-A,
thus leading to excessive high levels of ketone-bodies.
Subsequently, however, compensating regulations are
commencing: Increased insulin levels folloxving elevated
glucose concentrations support glucose assimilation;
increased lactate concentrations may flow into gluco-
neogenesis. Resynthesis of neutral fats is enhanced, keto-
acid concentrations decrease. In good coincidence with
these findings are the changes in maternal acid-base-
parameters, which indicate an acute metabolic acidosis
during infusion of ß-mimetic tocolytics.
There can be no doubt, that small molecules, like glucose,
lactate, pyruvate, acetoacetate and j3-hydroxybutyrate
readily pass across the placental membranes into the fetal
organism. Maternal high concentrations of acid metab-
olites are most likely to produce a fetal metabolic
acidosis. Catecholamines and catecholamine derivatives
themselves do cross the placenta in humans and addi-
tionally induce the typical /?-stihmlated responses in the
fetal organism itself. In placental and fetal tissues ß-
mimetic catecholamines are likely to be metabolized. The
two catecholamine degrading enzyme activities monoamine
oxidase and catechol-O-methyl transferase have been
identified in placental and fetal tissues, so that to some
extent inactivation and protection may be possible. In the
practical use it has to be realized, that during /ff-mimetic
tocolytic therapy glycogenolysis and lipolysis occur in the
mother äs well äs in the fetus. When after 2—3 hours of
ß-mimetic tocolytic infusion the therapy fails, a metabolic
acidosis, resulting from ingreased concentrations of acid
metabolites: lactate, acetoacetate, /?-hydroxybutyrate has
to be anticipated in the newborn. The glycogen depots
may be depleted and hypoglycemia is endangering
the newborn. After long-time therapy, however, the
initial ß-stimulated metabolic changes have balanced
and are likely to be of less importance. Infänts followed
up biochemically and neurologically for 18 months
after tocolytic therapy did not display any signs of
impairment.
Before starting a tocolytic therapy, fetal condition should
be evaluated carefully. In cases of severe reduction of
placental function, a preterm delivery may be more fa-
vourable to the fetus than any Prolongation of the patho-
logic pregnancy.
Keywords: Acidosis (metabolic), catecholamines (/^mimetic), glycogenolysis, labor (premature), lipolysis, supine hypo-
tensive syndrom, tocolysis.
Zusammenfassung
Einfluß von sympathicomimetischen tokolytischen
Substanzen auf den Feten
Die Ruhigstellung der Uterusmuskulatur durch Stimu-
lierung der /8-adrenergen Rezeptoren im Myometrium
findet als symptomatische Therapie vorzeitiger und
hyperaktiver Uteruskontraktionen zunehmend An-
wendung (Tab. I). Dabei stellt die relaxierende Wirkung
auf die Uterusmuskulatur nur eine Komponente aus dem
Gesamtkomplex der jS-stimulierten Reizbeantwortung dar.
Die Beurteilung möglicher Nebenwirkungen auf den Feten
hat aber das vollständige Spektrum der ß-stimulierten Ver-
änderungen zu berücksichtigen, das neben kardioäk-
zeleratorischen und vasodilatatorischen Wirkungen als
typische, über die Bildung von zyklischem 3'-5'-
Adenosinmonophosphat induzierte metabolische Ver-
änderungen auch eine Glykogenolyse und Lipolyse um-
faßt.
Der Fet kann in dem zunächst bei der Mutter durch die
tokolytische Therapie ausgelösten Reaktionsablauf einmal
indirekt über die kardiovaskulären und metabolischen
Alterationen des mütterlichen Organismus einbezogen
werden, zum anderen können nach diaplazentarem Über-
tritt der/?-mimetischen Substanz in den fetalen Organismus
dort selbst die gleichen Reaktionen stimuliert werden.
Die mütterliche Tachykardie allein ist für den Feten
ohne wesentliche Bedeutung. Durch ^-Stimulation in-
duzierte mütterliche periphere Vasodilatätion und
Hypotonie können aber, insbesondere bei hypotoner Aus-
gangssituation zu einer verminderten Durchblutung von
Uterus und Plazenta, zur Beeinträchtigung der Sauerstoff-
versorgung und damit zur akuten respiratorischen Pla-
zentainsuffizienz führen. Diese Situation kann sich vor
allem auch ergeben, wenn durch tokolytische Infusion
in Rückenlage ein Vena-cava^Syndrom begünstigt
wird. Andererseits kann jedoch die periphere Vasodilatä-
tion auch zu verbesserter uteroplazentarer Durchblutung
führen, vor allem wenn diese Wirkung zusätzlich zu einer
angestrebten Ruhigstellung des Uterus hinzutritt. Auf
diese Weise kann möglicherweise die Versorgung des
Feten intrauterin unter der Geburt und auch durch Lang-
zeittherapie bei EPH-Gestose verbessert werden.
Die typischen /J-stimulierten Stoffwechselveränderungen
haben erst in jüngerer Zeit eingehendere Untersuchung er-
fahren. Unter akuter tokolytischer Infusionstherapie
kommt es rasch zur Glykogenolyse, wobei vorwiegend
Muskelglykoyen gespalten wird, mit deutlichem An-
stieg der Konzentrationen von Laktat, Pyruvat und Glu-
kose im mütterlichen Blut; gleichzeitig erfolgt eine massive
J. Pcrinat. Med. 2 (197-0
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Insulininkretion. Ebenso rasch setzt die Lipolyse ein,
aus der ansteigende Konzentrationen von freien Fett-
säuren, freiem Glycerin, aber auch durch die Hemmung
der Metabolisierung von Azetyl-Co-A, von Ketonkörpern
wie Azetessigsäure und ß-Hydroxybuttersäure resultieren.
Nach etwa 2 bis 3 Stunden tokolytischer Infusion beginnen
sich diese Veränderungen zum Teil einzupendeln und
wieder auszugleichen: Die Resynthese von Neutralfetten
setzt ein und die Ketonkörperkonzentrationen bilden sich
zurück. Nach der beim Feten und Neugeborenen nachge-
wiesenen Tendenz der aktuellen pH-Werte zum sauren
Bereich, ebenso wie der Abnahme des Basenexcess' und die
Zunahme der Konzentrationen von Laktat und Pyruvat
muß angenommen werden, daß die niedermolekularen
Metabolite unmittelbar diaplazentar übergehen und auch
beim Fet, wie bei der Mutter zu einer metabolischen
Azidose beitragen. Diese Stoffwechselveränderungen
müssen berücksichtigt werden, falls ein Kind in dieser
akuten Phase tokolytischer Infusionstherapie geboren wird,
zum Beispiel nach Versagen eines Tokolyseversuchs. Nach
Langzeittherapie treten die Veränderungen im Kohlen-
hydrat- und Fettstoffwechsel wegen der ausgleichenden
Regulationen in ihrer Bedeutung zurück. Die nach
Langzeittherapie mit /8-mimetischen Tokolytica vereinzelt
beobachteten erhöhten Geburtsgewichte können einerseits
über das vermehrte Glukoseangebot, andererseits aber auch
durch die verbesserte uteroplazentare Durchblutung ge-
deutet werden. Biochemische und neurologische Verlaufs-
kontrollen und Nachuntersuchungen nach Langzeit-
therapie haben bisher bis zu einem Alter von 18 Monaten
keinen Anhalt für tokolysebedingte Veränderungen
oder Schädigungen ergeben.
Der diaplazentare Übergang von ß-mimetischen Kate-
cholaminderivaten wie sie zur Tokolyse Anwendung
finden ist erwiesen. Zu den durch die erhöhten mütterlichen
Metabolitkonzentrationen induzierten Stoffwechselverän-
derungen beim Feten, treten nun die im fetalen Organismus
selbst ausgelösten gesamten typischen ^-stimulierten
Effekte noch hinzu, so daß zum Beispiel bei unter oder
nach Tokolyse geborenen Kindern mit verminderten
Glykogendepots und der daraus resultierenden erhöhten
Gefährdung durch eine post-partuale Hypoglykämie zu
rechnen ist. In Plazentagewebe, wie auch in fetalen Or-
ganen liegen die Aktivitäten von Monoaminoxydase und
Katechol-O-methyltransferase, den Schlüsselenzymen von
Inaktivierung und Abbau von Katecholaminen vor, so daß
eine gewisse Limitierung der Katecholaminwirkung ge-
geben sein kann.
Bei Vorliegen ungünstiger intrauteriner Bedingungen für
den Feten, wie zum Beispiel durch chronische Plazentar-
insuffizienz sollte vor Beginn einer tokolytischen Therapie
mittels umfassender Diagnostik geprüft und abgewogen
werden, ob eine frühzeitige Entbindung unter Intensiv-
überwachung nicht günstigere Chancen für das dysmature
Kind bedeutet als eine Verlängerung der pathologischen
Schwangerschaft.
Schlüsselworte: Azidose (metabolische), Glykogenolyse, Katecholamine (/3-mimetische), Lipolyse, Tokolyse, Vena-
cava-Syndrom, Wehen (vorzeitig).
Resume
Effects des agents sympathicomimetiques sur le
foetus
Les catecholamines /?-mimetiques ont fait la preuve de
leur utilite dans le traitement des menaces d'accouche-
ment premature (tab. I). Jusqu'il y a peu de temps, les
effets foetaux et neo-nataux de ces substances avaient ete
etudies de fagon tres sommaire. La Stimulation des fibres
/?-produit differents phenomenes, la relaxation uterine en
est un parmi tant (Tautres. Des effets egalement im-
portants de cette activite sont la tachycardie, la vaso-
dilatation, Fhypotension, ainsi que le glycogenolyse
et al lipolyse. Si on veut etudier Pinfluence de la relaxation
uterine par les /?-mimetiques, il faut tenir compte de toutes
les formes de reaction, tant cardiovasculaires que meta-
boliques, du foetus a la Stimulation ß.
Les j8-mimetiques agissent de deux fagons sur le foetus:
1° de fagon indirecte, par leur action sur Fetat cardio-
vasculaire et le metabolisme de la mere.
2° directement, l'agent myorelaxant traverse 'le placenta et
produit ces effets chez le foetus.
L'hypotension maternelle, engendree par la relaxation
uterine, peut avoir des consequences funestes pour le
foetus, principalement, lorsque apparait une hypotension
de decubitus, et une chute du debit uteroplacentaire.
II est donc preferable de placer la patiente en decubitus
lateral pendant l'administration de /?-mimetiques.
D'un autre cöte, il se produit une vasodilatation peri-
pherique associee a une augmentation de l'amplitude du
pouls dues au fait que la pression arterielle systolique .teste
inchangee lorsque la diastolique s'abaisse; ceci provoque
une elivation du debit cardiaque maternel et par voie de
consequence une augmentation de la perfusion pla-
centaire et de l'apport d'oxygene au foetus. Cest en
particulier le cas, lorsqu'il existe une insuffisance chronique
placentaire.
L'elivation du poids de naissance observee apres admi-
nistration de longue duree de jS-mimetiques peut s'expliquer
par Famelioration de la circulation utero-placentaire, ou
par Taugmentation de la glycemie ou par les deux a le
fois.
Des le debut d'une perfusion de jS-mimetiques apparaissent
de phenomenes de lypolyse et de glycogenolyse. Les
depöts de glycogfene, surtout musculaires, sont mo-
bilises, ce qui se traduit par une elevation des taux de
lactate. La lipolyse borsque en mobilisant les depöts de
graisse neutre, provoque une augmentation des acides
J. Pcrinat. Mcd. 2 (1974)
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gras libres. La concentration elevee de ceux-ci bloque le
metabolisme de l'acetyl co-enzyme A, et aboutit a la
production excessive de corps cetoniques. Cependant, des
mecanismes compensateurs se mettent en action imme-
diatement. L'elevation de la glycemia entraine une aug-
mentation des taux d'insuline; la concentration elevee
en lactate provoque une gluconeogenese. U y a resynthese
des graisses neutres et diminution des corps cetoniques.
Ces faits sont confirmes par Petude des parametres de
l'equilibre acido-basique maternel, qui montrent Texistence
d'une acidose metabolique aigue pendant le perfusion des
/J-mimetiques.
II n'est pas douteux que les petites molecules, telles que
glucose, lactate, pyruvate, aceto-acetate et /?-hydroxi-
butyrate traversent rapidement la barriere placentaire. La
concentration elevee de ces metabolites acides dans le
sang maternel provoque evidemment une acidose
metabolique foetale. Les catecholamines et leurs derives
traversent le placenta humain et produisent leurs effets
/J-mimetiques directement sur le foetus. Les jS-stimulants
sont vraissemblablement metabolises par le placenta et
les tissus f oetaux. Deux enzymes necessaires au catabolisrne
des jS-mimetiques a savoir, la monoaminoxydase et la
catechol-o-methyl trans ferase ont ete isolees du placenta
et des tissus foetaux.
De cette fa^on, il semble que les /?-stimulants soient in-
actives dans Porganisme du foetus, et que celui-ci s'en
protege jusqu'ä un certain degre.
On doit bien s'imaginer qu'au töurs d'une therapeutique
tocolytique par les /?-mimetiques, la glycogenolyse et la
lipolyse apparaissent tant chez la mere que chez le foetus.
Lorsqu'on constate un echec de la therapeutique apres une
perfusion de deux ä trois heures de /?-stimulants, Tacidose
metabolique due ä Televation des taux de metaboliques
acides (lactate — acetoacetate — /?-hydroxybutirate) doit
etre prevue. Les reserves en glycogene peuvent etre
epuisees et on sait que Phypoglycemie est dangereuse
pour le foetus.
Au contraire, lors des therapeutiques de longue duree,
les modfications metaboliques initiales dues aux
/S-stimulants auront pu £tre neutralisees et presenteront
alors une moindre importance. Les enfants etudies du
point de vue biochemique et neurologique jusqu'ä 18
mois apres therapeutique tocolytique ne presentent
aucun trouble.
Avant de commencer un traitament tocolytique, i l faudra
evaluer minutieusement letat de foetus, en cas de reduction
severe de la fonction placeritaire, une naissance prematuree
sera generalement preferable a la Prolongation d'une
grossesse pathologique.
Mots-cles: Acidose metabolique, /?-mimetiques, glycogenolyse, lipolyse, hypotension de decubitus, tocolyse travail
premature.
Bibliography
[1] AGATHOPOULOS, A., D. NICOLOPOULOS, N. MAT-
SANIOTIS, C. PAPADATOS: Biochemical changes of
catechol-O-methyl transferase during development of
human liver. Pediatrics 47 (1971) 125
[2] AHLQUIST, R. P.: A study of the adrenotropic re-
ceptors Amer. J. Physiol. 153 (1948) 586
[3] BARDEN, T. P., R. W. STANDER: Myometrial and
cardiovascular effects of an adrenergic blocking drug
in human pregnancy. Amer. J. Obstet. Gynec. 101
(1968) 91
[4] BARDEN, T. P.: Inhibition of human premature labor
by Mesuprine hydrochloride. Obstet. Gynec. 37
(1971) 98
[5] BARDEN, T. P.: Effect of ritodrine on human uterine
motility and cardiovascular responses in term labor
and the early postpartum state. Amer. J. Obstet.
Gynec. 112 (1972) 645
[6] BAUMGARTEN, K.: Über die Inhibition der Uterus-
motilität am graviden Organ. W. klin. Wschr. 80
(1968) 567
[7] BAUMGARTEN, K., H. FRÖHLICH, A. SEIDL, F. LIM-
RACHMAT, K. SOKOL: Über einen neuen intravenös
anwendbaren Wehenhemmer ohne Kreislaufwirkung
W. klin. Wschr. 81 (1969) 102
[8] BAUMGARTEN, K., H. FRÖHLICH, A. SEIDL, K. SOKOL
F. LIM-RACHMAT, R. HAGER: A new /?-sympatho-
mimetic preparation for intravenous and oral In-
hibition of uterine contractions. Europ. J. Obstet.
Gynec. 2 (1971) 69
[9] BAUMGARTEN, K.: Klinische Erfahrungen mit dem
Wehenhemmer Ritodrine. In: SALING, E., F. J.
SCHULTE: Perinatale Medizin, Band II. 3. Deutscher
Kongreß für Perinatale Medizin, Berlin 1970, Thieme,
Stuttgart 1972
[10] BERTOLA, R. P., A. MARQUEZ, A. O. PAN: Estudio de
l'accion de la orciprenalina en obstetrica. Obstet.
Ginec. Lat. Amer. 28 (1970) 255
[11] BIENIARZ, J., M. MOTEW, A.SCOMMEGNA: Uterine
and cardiovascular efFects of Ritodrine in premature
labor. Obstet. Gynec. 40 (1972) 65
[12] BODEN, W., H. v. D. CRABBEN: Wehenhemmung mit
einer neuen ß-adrenergen Substanz. Med. Welt 21
(1970) 1342
[13] CASTREN, O., S. SAARIKOSKI: Die Metaboliten des
3H-Nor-adrenalin in dem Homogeiiat von Placenta,
Uterus und Menschenfötus. In: NAVRATIL, E.:
Vorträge u. wissenschaftl. Beitr. 5. Akad. Tagung
dtschspr. Prof. u. Priv. Doz. f. Gebh. ü. Gynäk.
1968. Thieme, Stuttgart 1971
[14] CONRADT, A., V. UNBEHAUN: Lipolyse und Keton-
ämie während der Infusion von Th 1165a. In: DUDEN-
HAUSEN, J. W., E. SALING: Perinatale Medizin,
Band IV. 5. Deutscher Kongreß für Perinatale
Medizin Berlin 1972. Thieme, Stuttgart 1973
[15] CRAWFORD, J. S.: Caesarean section and the an-
aesthesist. In: BOSSART, H., J. M. CRUZ, A. HUBER,
L. S. PROD'HOM, J. SISTEK: Perinatal Medicine. 3rd
J. Pcrinat. Med. 2 (1974)
Unbehaun, Effects of sympathomimetic tocolytic agents 27
European Congress of Perinatal Mediane, Lausanne
1972. Huber, Bern-Stuttgart-Wien 1973
[16] EGGIMANN, U.: Dilydrin, ein j9-Mimetikum als
Wehenhemmer. Schweiz. Z. Gynäk. Geburtsh. 2
(1971) 209
[17] EPPS, H. M. R.: The development of amine oxidase
activity by human tissue. Biochem. J. 39 (1945) 37
[18] ESKES, T., L. STOLTE, J. SEELEN, H. D. MOED, C.
VOGELSANG: Epinephrine derivates and the activity
of the human uterus II. Amer. J. Obstet. Gynec. 92
(1965) 871
[19] ESKES, T. K. A. B.: Prevention and management of
early labor. In: HUNTINGFORD, P. J., R. W. BEARD,
F. E. HYTTEN, J. W. SCOPES: Perinatal Medicine. 2nd
European Congress of Perinatal Medicine, London
1970. Karger, Basel-München-Paris-London-New
York-Sidney 1971
[20] ESKES, T. K. A. B.: Vergleichende Untersuchungen
zur Tokolyse mit /?-Adrenergika. In: SALING, E.,
F. J. SCHULTE: Perinatale Medizin Band II. 3.
3. Deutscher Kongreß für Perinatale Medizin Berlin
1970. Thieme, Stuttgart 1972
[21] ESKES, T. K. A. B., J. DE HAAN: The influence of
ß-mimetic catecholamines upon the fetal circulation.
Z. Geburtsh. Perinat. 176 (1972) 97
[22] ESTEBAN-ALTIRRIBA, J., O. GAMISSANS, P. DURAN,
J. CALAT, A. RENE: Administration of /?-mimetic
agents to the mother äs a conservative therapy in
cases of intrapartum fetal acidosis. In: SALING, E.,
J. W. DUDENHAUSEN: Perinatale Medizin Band III.
4. Deutscher Kongreß für Perinatale Medizin Berlin
1971. Thieme, Stuttgart 1972
[23] FERLINZ, R., H. J. STADELER, H. SCHNITZLER, U.
RICK: Der Einfluß von Th 1165 a (Berotec) auf
Serum-Kalium und Blutzucker. Int. J. clin. Pharmacol.
Beiheft 4 (1972) 59
[24] FITZGERALD, J. D.: /?-adrenerge Stimulantien und
Antagonisten. In: KUEMMERLE, H. P., E. R. GARRET,
K. H. SPITZY: Klinische Pharmakologie und Phar-
makotherapie. Urban & Schwarzenberg, München-
Berlin-Wien 1971
[25] GAMISSANS, O., J. ESTEBAN-ALTIRRIBA, V. MAIQUES:
Inhibition of human myometrical activity by a new
ß-adrenergic drug (Du-21220). J. Obstet. Gynaec.
Brit. Cwlth. 76 (1969) 656
[26] GAMISSANS, O., J. ESTEBAN-ALTIRRIBA, J. CALAF:
The treatment of intrapartum fetal acidosis by intra-
venous infusion of j8-adrenergic drugs to the mother.
In: HUNTINGFORD, P. J., R. W. BEARD, F. E. HYTTEN,
J. W. SCOPES: Perinatal Medicine. 2nd European
Congress of Perinatal Medicine London 1970. Karger,
Basel-München-Paris-London-New York-Sidney 1971
[27] HALLER, U., D. SCHENK, B. RÜNNEBAUM, H. RÜTT-
GERS, U. LORENZ, F. KUBLI: Langzeitbehandlung mit
Betamimetika während der Schwangerschaft und
Verhalten von Oestriol. HPL und biparietalem Durch-
messer. In: DUDENHAUSEN, J. W., E. SALING: Peri-
natale Medizin Band IV. 5. Deutscher Kongreß für
Perinatale Medizin Berlin 1972. Thieme, Stuttgart
1973
[28] HÜTER, J.: Situationsgerechte Toko- und Tonolyse
in der Geburtshilfe. Med. Welt 19 (1968) 2023
[29] HÜTER, J., CH. RIPPERT, C. MEYER: Wehenhemmung
mit welchem /S-Mimetikum (Berotec, Ritodrine,
Dilatol)? Geburtsh. u. Frauenheilk. 32 (1972) 97
[30] JUNG, H.: Maintenance of pregnancy under the
aspects of uterus-inhibiting substances. In: GIBIAN,
H., E. PLOTZ: Mammalian Reproduction. Springer,
Berlin-Heidelberg-New York 1970
[31] JUNG, H., P. ABRAMOWSKI, F. K. KLÖCK, W.
SCHWENZEL: Zur Wirkung <x- und ß-adrenergischer
Substanzen am menschlichen Uterus und Neben-
wirkungen auf Mutter und Kind. Geburtsh. u.
Frauenheilk. 31 (1971) 11
[32] JUNG, H.: Zur Physiologie des Uterus-Muskels unter
Berücksichtigung zellulärer und neuro-humoraler
Regelvorgänge bei der Ruhigstellung des schwangeren
Uterus. In: SALING, E., F. J. SCHULTE: Perinatale
Medizin Band II. 3. Deutscher Kongreß für Perinatale
Medizin Berlin 1970. Thieme, Stuttgart 1972
[33] KLÖCK, F. K., H. CHANTRAINE, A. ETZRODT, B.
LIEDTKE, H. J. SCHULTE: Der Einfluß des ß-Stimu-
lators Th 1165 a auf mütterliche und fetale Stoff-
wechsel-Parameter. In: DUDENHAUSEN, J. W., E.
SALING: Perinatale Medizin Band IV. 5. Deutscher
Kongreß für Perinatale Medizin Berlin 1972. Thieme,
Stuttgart 1973
[34] KOEPCKE, E., G. SEIDENSCHNUR: Erfahrungen mit
der medikamentösen Wehenhemmung. Dtsch. Ges.-
wesen 28 (1973) 546
[35] KÜNZEL, W., J. REINECKE: Der Einfluß von Th
1165 a auf die Gaspartialdrucke und auf kardiovasku-
läre Parameter von Mutter und Fetus. Zugleich eine
quantitative Analyse der Wehentätigkeit. Z. Ge-
burtsh. Perinat. 177 (1973) 81
[36] LANDESMAN, R., K. H. WILSON, E. M. COUTINHO,
J. M. KLIMA, R. S. MARCUS: The relaxant action of
ritodrine, a sympathomimetic amine, on the uterus
during term labor. Amer. J. Obstet. Gynec. 110
(1971) 111
[37] LANG, N., O. BELLMANN, H. HINCKERS, M. HANS-
MANN, H. SCHLEBUSCH: Einfluß der Tokolytika auf
den KohlenhydratstofFwechsel. In: DUDENHAUSEN,
J. W., E. SALING: Perinatale Medizin Band IV.
5. Deutscher Kongreß für Perinatale Medizin Berlin
1972. Thieme, Stuttgart 1973
[38] LIPPERT, T. H., F. KUBLI, H. RÜTTGERS: Die hyper-
glykämische Aktivität von Tokolytika. Klin. Wschr.
50 (1972) 119
[39] LLIXIONA, J., L. FERRERES : La accion uteroinhibidora
de un nuevo simpaticomimetico /J-dervado de la
orciprenalina, el Th 1165 a en obstetrica. Toko Ginec.
Pract. 28 (1969) 763
[40] MAN, N. K., P. KELLER, W. HALLAUER, J. SCHIR-
MEISTER: Die Hypokaliämie und Kaliurie nach intra-
venöser Gabe eines Symphathicomimetikums beim
Menschen. Verh. Dtsch. Ges. Inn. Med. 73 (1967)
1045
J. Perinat. Med. 2 (1974)
28 Unbehaun, EfFects of sympathomimetic tocolytic agents
[41] MORGAN, C. D., M. SANDLER, M. PANIGEL: Placental
transfer of catecholamines in vitro and in vivo. Amer.
J. Obstet. Gynec. 112 (1972) 1068
[42] MOSLER, K. H., H. G. ROSENBOOM: Neuere Mög-
lichkeiten einer tokolytischen Behandlung in der
Geburtshilfe. Z. Geburtsh. Perinat. 176 (1972) 85
[43] MOSLER, K. H.: Potenzierung der Uterushemmung
j8-adrenerger Sympathomimetika durch neue kardio-
protektive Substanzen. In: JUNG, H.: Methoden der
pharmakologischen Geburtserleichterung und Uterus-
Relaxation. Thieme, Stuttgart 1972
[44] MOSLER, K. H.: Symptomatische Therapie der
drohenden Frühgeburt. In: SALING, E., F. J. SCHULTE:
Perinatale Medizin Band II. 3. Deutscher Kongreß
für Perinatale Medizin, Berlin 1970. Thieme, Stuttgart
1972
[45] NEUBÜSER, D.: Vergleichende Untersuchungen über
zwei Tokolytika (TV 399 und Buphenin). Geburtsh.
u. Frauenheilk. 32 (1972) 781
[46] NEUMANN, H., U. MANTEUFFEL: Behandlung der
drohenden Fehl- und Frühgeburt mit Duvadilan.
Zbl. Gynäk. 92 (1970) 1100
[47] NEUMANN, H., P. HENGST: Behandlung der drohenden
Früh- und Fehlgeburt mit Dilatol. Zbl. Gynäk. 93
(1971) 849
[48] NICOLOPOULOS, D., A. AGATHOPOULOS, C. DANE-
LATOU-ATHANASSIADOU, M. BAFATAKi: Urinary ex-
cretion of phenolic and indolic compounds, meta-
catecholamines, and vanillinmandelic acid by f ull-term
and premature infants. Pediatrics 41 (1968) 777
[49] RIPPERT, GH., J. HÜTER, R. BÄRTSCHI: Intravenöse
Langzeit-Wehenhemmung mit ß-Mimetika und Anta-
gonisierung der Nebenwirkungen. Geburtsh. u.
Frauenheilk. 31 (1971) 710
[50] RIPPERT, GH., J. HÜTER, F. KUBLI, C. MEYER: Medi-
kamentöse Therapie der hyperaktiven, hyperonen und
diskordanten Wehentätigkeit sub partu. Geburtsh. u.
Frauenheilk. 32 (1972) 393
[51] RUPPEN, M., J. SCHMID: Der Einfluß kurzzeitiger
Infusionen von Dylidrin auf den Säure-Basen-Haus-
halt und den Glukosestoffwechsel unter der Geburt.
In: DUDENHAUSEN, J. W., E. SALING: Perinatale
Medizin Band IV. 5. Deutscher Kongreß für Peri-
natale Medizin Berlin 1972. Thieme, Stuttgart 1973
[52] SALING, E.: Prämaturitäts- und Dysmaturitäts-
Präventionsprogramm (PDP-Programm). Z. Ge-
burtsh. Perinat. 176 (1972) 70
[53] SANDLER, M., C. R. J. RUTHVEN, S. F. CONTRACTOR,
C. WOOD, R. T. BOOTH, J. H. M. PINKERTON: Trans-
mission of noradrenaline across the human placenta.
Nature 197 (1963) 598
[54] SCHNELL, J. D., H. STOCKHAUSEN: Tokographische
Vergleichsuntersuchungen bei Anwendung verschie-
dener tokolytischer Substanzen. Arch. Gynäk. 211
(1971) 277
[55] SCHOLTES, G.: Blutzuckerverhalten bei der Behand-
lung mit den Wehenhemmern Buphenin (Dilatol)
und Th 1165a. Z. Geburtsh. Perinat. 177 (1973) 90
[56] SHENKER, L.: Effect of isoxsuprine on fetal heart
rate and fetal electrocardiogram. Obstet. Gynec. 26
(1965) 104
[57] STANDER, R. W., BARDEN; T. P., J. F. THOMPSON,
W. R. PUGH, C. E. WERTS: Fetal cardiac effects of
maternal isoxsuprine infusion. Amer. J. Obstet.
Gynec. 89 (1964) 792
[58] STOCKHAUSEN, H., J. SCHNELL, K. RÜTHER: Die
Tokolyse unter der Geburt — eine tokographische
Vergleichsuntersuchung bei Anwendung verschie-
dener tokolytischer Substanzen. Geburtsh. u. Frauen-
heilk. 32 (1972) 51
[59] THIERY, M., R. M. J. DEROM, H. E. VAN KETS, A. F.
DE SCHAEPDRYVER, P. J. BERNARD, S. A. C. BEKAERT,
C. M. J. HOOFT, F. DEROM, G. ROLLY, H. J. R.
ROELS: Phaeochromocytoma in pregnancy. Amer. J.
Obstet. Gynec. 97 (1967) 21
[60] THOMPSON, R. H. S., A. TICKNER: Observations on
the mono-amine-oxidase activity of placenta and
uterus. Biochem. J. 45 (1949) 125
[61] UNBEHAUN, V., A. CONRADT, S. HELLER, H. WEBER:
Einfluß von Th 1165 a auf die Konzentrationen von
Glucose, Insulin, Kohlenhydratmetaboliten, Serum-
elektrolyten sowie humanem placentarem Lactogen.
In: DÜDENHAUSEN, J. W., E. SALING: Perinatale
Medizin Band IV. 5. Deutscher Kongreß für Peri-
natale Medizin, Berlin 1972. Thieme, Stuttgart 1973
[62] UNBEHAUN, V., A. CONRADT, E. MEISWINKEL: As-
pekte der Therapie drohender Frühgeburten. Med.
Welt 23 (1972) 1920
[63] VAHRSON, H., H. J. SCHWARZ: Zur Anwendung ß-
adrenergischer Substanzen in der Therapie schwerer
Gestosen ohne Gefährdung des Kindes. Geburtsh. u.
Frauenheilk. 31 (1971) 536
[64] WEIDINGER, H., D. MOHR: Blutglucose und im-
munreaktives Insulin unter dem Einfluß von Beso-
partin (Th 1165 a, /J-Sympathicomimeticum) und
Isoptin bei Schwangeren mit und ohne tokolytische
Therapie. In: DUDENHAUSEN, J. W., E. SALING:
Perinatale Medizin Band IV. 5. Deutscher Kongreß
für Perinatale Medizin, Berlin 1972. Thieme, Stuttgart
1973
[65] WEIDINGER, H., W. WIEST, S. DIETZE, K. WITZEL:
Die Auswirkungen langzeittiger Wehenhemmung auf
das Neugeborene und den Säugling. In: DUDEN-
HAUSEN, J. W., E. SALING: Perinatale Medizin, Band
IV. 5. Deutscher Kongreß für Perinatale Medizin,
Berlin 1972. Thieme, Stuttgart 1973
[66] WESELIUS-DE CASPARIS, A., M. THIERY, A. Yo LE
SIAN, K. BAUMGARTEN, J. BRQSENS, O. GAMISSANS,
J. G. STOLK, W. VIVERI: Results of double-blind,
multicentre study with Ritödrine in premature labour.
Brit. Med. J. 3 (1971) 144
[67] WOLFF, C. H.: Die medikamentöse Behandlung der
vorzeitigen Wehentätigkeit. Z. Geburtsh. Gynäk.
167 (1967) 68
[68] WOLFF, C. H.: Über die Behandlung der drohenden
Frühgeburt mit Duvadilan. Geburtsh. u. Frauen-
heilk. 27 (1967) 402
J. Perinat. Med. 2 (1974)
Unbehaun, Effects of sympathomimetic tocolytic agents 29
[69] WOLFF, C. H.: Wirkung einer ß-rezeptoren-stimu-
lierendcn Substanz (Buphenin) auf den Blutdruck
normo- und hypertoner Frauen während der Schwan-
gerschaft. Dtsch. med. Wschr. 95 (1970) 2332
[70] WOLFF, C. H.: Fetale Begleitsymptomatik während
der Dilatol-Dauertropfinfusion. Zbl. Gynäk. 92
(1970) 1307
[71] WOLFF, C. H.: Synopsis der klinischen Erfahrungen
mit Dilatol als Tokolyticum. In: SALING, E., F. J.
SCHULTE: Perinatale Medizin, Band II. 3. Deutscher
Kongreß für Perinatale Medizin Berlin 1970. Thieme,
Stuttgart 1972
[72] ZILIANTI, M., J. ALLER: Action of orciprenaline on
uterine contractility during labor, maternal cardio-
vascular System, fetal heart rate, and acid base balance.
Amer. J. Obstet Gynec. 109 (1971) 1073
[73] ZLATNIK, F. J.: The applicability of labor Inhibition
to the problem of prematurity. Amer. J. Obstet.
Gynec. 113 (1972) 704
[74] ZUSPAN, F. P., W. H. WHALEY, G. H. NELSON,
R. P. AHLQUIST: Placental transfer of epinephrine.
I. Maternal-fetal metabolic alterations of glucose and
non esterified fatty acids. Amer. J. Obstet. Gynec.
95 (1966) 284
[75] ZUSPAN, F. P.: Premature Labor: Its management and
therapy. J. Reprod. Med. 9 (1972) 93




J. Perinät. Med. 2 (1974)
